Marc Yoskowitz

Marc Yoskowitz brings to the Board extensive leadership and management experience in the pharmaceutical industry. He has served on the Board of Directors at Mereo BioPharma since 2022, where he is a member of the R&D Committee, and previously held a Board position at Endo, Inc. in 2025.

Mr. Yoskowitz is currently CEO of Evozyne, Inc., a venture capital–backed biotech designing novel proteins leveraging generative AI. Previously, he served as EVP and Chief Strategy Officer, Life Sciences at Tempus AI, Inc. Prior to Tempus, Mr. Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira and was a member of the Executive Committee.

Earlier in his career, Mr. Yoskowitz led business development at a specialty pharmaceutical company; spent eight years at McKinsey & Company, where he was an Associate Principal; and began his career as an M&A lawyer at Davis, Polk & Wardwell in New York.

Mr. Yoskowitz received a bachelor’s degree magna cum laude from Washington University in St. Louis and holds a J.D. from Columbia University School of Law.